Commonwealth Equity Services LLC Takes $293,000 Position in Guardant Health, Inc. (NASDAQ:GH)

Commonwealth Equity Services LLC acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 9,586 shares of the company's stock, valued at approximately $293,000.

Other hedge funds have also recently bought and sold shares of the company. R Squared Ltd acquired a new stake in Guardant Health in the fourth quarter valued at about $26,000. SBI Securities Co. Ltd. bought a new position in shares of Guardant Health in the fourth quarter worth about $43,000. Jones Financial Companies Lllp boosted its stake in shares of Guardant Health by 43.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after purchasing an additional 817 shares in the last quarter. Van ECK Associates Corp grew its holdings in shares of Guardant Health by 47.4% during the 4th quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock valued at $88,000 after purchasing an additional 929 shares during the last quarter. Finally, KBC Group NV increased its position in Guardant Health by 63.6% during the 4th quarter. KBC Group NV now owns 5,658 shares of the company's stock worth $173,000 after purchasing an additional 2,200 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Guardant Health Price Performance

Shares of GH traded up $2.57 during trading hours on Friday, hitting $43.71. The stock had a trading volume of 2,167,377 shares, compared to its average volume of 2,142,927. The firm has a 50 day simple moving average of $43.57 and a 200-day simple moving average of $35.78. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $50.89. The firm has a market capitalization of $5.39 billion, a P/E ratio of -12.28 and a beta of 1.45.

Remove Ads

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Equities analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on GH shares. JPMorgan Chase & Co. lifted their price target on Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Morgan Stanley boosted their target price on shares of Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a report on Thursday, March 6th. Mizuho assumed coverage on shares of Guardant Health in a research note on Thursday. They set an "outperform" rating and a $55.00 price target for the company. Piper Sandler boosted their price objective on shares of Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Finally, Stephens restated an "overweight" rating and issued a $55.00 price objective on shares of Guardant Health in a report on Wednesday, March 26th. Twenty analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $49.00.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.